Critical Illness-related Corticosteroid Insufficiency is Common in Covid-19 and Treatment Provide Survival Benefit

Résumé

Abstract PurposeCovid-19 is a severe lethal disease characterized with pneumonia and acute respiratory distress syndrome. We aimed to analyze the prevalence of critical illness-related corticosteroid insufficiency (CIRCI) in Covid-19 patients treated in intensive care unit and whether treatment of it would create any survival benefit. MethodsA total of 119 Covid-19 patients in intensive care unit were enrolled into the study. All patients received treatment for Covid-19 according to national guideline including hydroxychloroquine, favipiravir, antibiotics including azithromycin and oseltamivir in some patients. Basal cortisol below 10 µg/dl were accepted as CIRCI and above 34 µg/dl as intact HPA axis. Patients between them were introduced 1 µg cosynthropin stimulation test and delta cortisol below 9 µg/dl were also accepted as CIRCI. All patients who got diagnosis received hydrocortisone 300 mg/day until clinical condition stabilized. Mortality rate was recorded, then. ResultsCIRCI was detected in 50.4% of cases and mean plasma ACTH level was 14.8±6.0 pg/ml. Patients below age 65 had a statistically higher risk (63.4 % vs. 40.2%, p=0.012). Presence of comorbidity did not increase the risk of CIRCI (47.3% vs. 62.5%, p=0.18). Also, severity of pulmonary involvement and intubation did not increase the risk of CIRCI. Total mortality rate was 49.5% and not different in patients with and without CIRCI (45.0% vs. 54.5%, p=0.31) indicating benefit of corticosteroid treatment. ConclusionCIRCI is common in Covid-19 patients treated in intensive care unit and treatment of CIRCI provide survival benefit.

Citer ce document

Accès au document

Ce document est hébergé sur son dépôt institutionnel d'origine.

Auteur(s)

Statistiques

Consultations : 1

Téléchargements : 0